APP and Alzheimer disease: More recently, the curcumin analog C1 was shown to activate TFEB and increase lysosome biogenesis, which in turn decreased beta-amyloid precursor protein and Tau pathology in three AD animal models (5XFAD, P301S, and 3XTg-AD) [32].